Saltar ao contenido
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzado
  • <i>ASXL1/TET2</i> genotype-bas...
  • Citar
  • Text this
  • Enviar este rexistro por email
  • Imprimir
  • Exportar rexistro
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Permanent link
<i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

<i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

Not available.

Detalles Bibliográficos
Main Authors: Clifford M. Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly Chien, Danielle Hammond, Terra L. Lasho, Christy M. Finke, Christopher Dean, Anuya Natu, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Rami S. Komrokji, Najla A. Ali, Eric Padron, Guillermo Montalban-Bravo, Mrinal M. Patnaik
Formato: Artigo
Idioma:English
Publicado: Ferrata Storti Foundation 2024-06-01
Series:Haematologica
Acceso en liña:https://haematologica.org/article/view/11659
  • Existencias
  • Descripción
  • Títulos similares
  • Staff View

Internet

https://haematologica.org/article/view/11659

Títulos similares

  • CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
    por: Evandro D. Bezerra, et al.
    Publicado: (2021-03-01)
  • P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
    por: Moritz Binder, et al.
    Publicado: (2023-08-01)
  • Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
    por: Moritz Binder, et al.
    Publicado: (2022-03-01)
  • The expression of ASXL3 in prostate cancer
    por: ZHANG Jinhui, et al.
    Publicado: (2024-03-01)
  • Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
    por: Maya C. Ayoub, et al.
    Publicado: (2023-11-01)

Opciones de procura

  • Historial de Procuras
  • Procura avanzada

Buscar Máis

  • Revisar o catálogo
  • Lista alfabética
  • Explore Channels
  • Reservas de curso
  • Novos exemplares

Necesita Axuda?

  • Consello de procura
  • Consulte a un Bibliotecario
  • Preguntas Frecuentes